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accumulation of inosine, 29-deoxy-inosine (dIno), guanosine, and
29-deoxy-guanosine (dGuo) in all cells, especially lymphocytes.
Treatments are available and curative for PNP deficiency, butFrom aNewborn Screening, Biochemistry and Pharmacology Laboratory, Paediatric
Neurology Unit and Laboratories, Neuroscience Department, Meyer Children’s Hos-
pital, Florence; bthe Department of Neurosciences, Psychology, Pharmacology and
Child Health, University of Florence; cMeyer Children’s University Hospital,
Florence; dthe Department of Health Sciences, University of Florence; eZentrum fur
Kinderheilkunde und Jugendmedizin, Centrum fuer Chronische, Immundefizienz–
Universitaet Freiburg; fthe Division of Clinical Immunology and Transfusion
Medicine, Department of LaboratoryMedicine, Karolinska Institutet, Karolinska Uni-
versity Hospital Huddinge, Stockholm; gthe Translational Centre for Regenerative
Medicine (TRM), University of Leipzig; hthe Department of Allergy and Immunology,
Children’s Hospital Lund, Skane University Hospital, Lund; ithe Institute of Cellular
Medicine, Newcastle University; jthe Division of Hematology and Oncology, Chil-
dren’s Hospital, Boston; kthe Department of Pediatric Oncology, Dana-Farber Cancer
Institute, Boston; lAntalya Education and Research Hospital, Pediatric Immunology
and Allergy, Antalya; mP€adiatrische H€amatologie und Onkologie, Universit€atsklini-
kum Schleswig-Holstein, Campus L€ubeck; nthe Department of General Pediatrics
and oPediatric Rheumatology and Immunology, University Children’s Hospital Muen-
ster; pthe Department of Medicine, Duke University, Medical Center, Durham; qthe
Department of Pediatric Immunology andAllergy, Ankara UniversityMedical School,
Ankara; and rthe Division of Immunology, Children’s Hospital, Boston.
*These authors contributed equally to this work.
Supported in part by a donation from Famiglia Cassigoli (to C.A.) and a grant from the
University of Florence (to C.A. and G.l.M.), Meyer Children’s University Hospital
(to M.R.), and the Tuscany (Italy) region (to C.A., G.l.M., and M.R.). Sigma-Tau
Pharmaceuticals provided grant support to M.H. and I.S. Orphan Europe provided
grant support to E.G. and F.R.
Disclosure of potential conflict of interest: I. Santisteban and P. Bali have received
research support from Sigma-Tau Pharmaceuticals. M. Hershfield has received
research support, consultancy fees, and travel support from Sigma-Tau Pharmaceuti-
cals. L. D. Notarangelo is a board member for the Program in Molecular and Cellular
Medicine, Boston, and for Pediatric University Hospital ‘‘Meyer,’’ Florence, Italy; is
employed by Boston Children’s Hospital; has received research support from the
National Institutes of Health and the March of Dimes; and has received royalties from
UpToDate. The rest of the authors declare that they have no relevant conflict of interest.
Received for publication July 15, 2013; revised December 27, 2013; accepted for publi-
cation January 3, 2014.
Available online April 24, 2014.
Corresponding author: Chiara Azzari,MD, Department of Health Sciences, University of
Florence, Meyer Children’s University Hospital, Viale Pieraccini 24, 50139 Firenze,
Italy. E-mail: chiara.azzari@unifi.it.
0091-6749/$36.00
 2014 American Academy of Allergy, Asthma & Immunology
http://dx.doi.org/10.1016/j.jaci.2014.01.040their efficacy depends on the early approach. PNP–combined
immunodeficiency complies with the criteria for inclusion in a
newborn screening program.
Objective: This study evaluate whether mass spectrometry can
identify metabolite abnormalities in dried blood spots (DBSs)
from affected patients, with the final goal of individuating the
disease at birth during routine newborn screening.
Methods: DBS samples from 9 patients with genetically
confirmed PNP–combined immunodeficiency, 10,000 DBS
samples from healthy newborns, and 240 DBSs from healthy
donors of different age ranges were examined. Inosine, dIno,
guanosine, and dGuo were tested by using tandem mass
spectrometry (TMS). T-cell receptor excision circle (TREC) and
kappa-deleting recombination excision circle (KREC) levels
were evaluated by using quantitative RT-PCR only for the 2
patients (patients 8 and 9) whose neonatal DBSs were available.
Results: Mean levels of guanosine, inosine, dGuo, and dIno were
4.4, 133.3, 3.6, and 3.8 mmol/L, respectively, in affected patients.
No indeterminate or false-positive results were found. In patient
8 TREC levels were borderline and KREC levels were
abnormal; in patient 9 TRECs were undetectable, whereas
KREC levels were normal.
Conclusion: TMS is a valid method for diagnosis of PNP
deficiency on DBSs of affected patients at a negligible cost. TMS
identifies newborns with PNP deficiency, whereas TREC or
KREC measurement alone can fail. (J Allergy Clin Immunol
2014;134:155-9.)
Key words: Purine nucleoside phosphorylase, severe combined
immunodeficiency, newborn screening, tandem mass spectrometry,
late-onset, delayed-onset, purine nucleoside phosphorylase–combined
immunodeficiency, T-cell receptor excision circle, inherited disorder
Primary immunodeficiencies are a group of severe diseases that
affect the immune system. The most severe phenotype is severe
combined immunodeficiency (SCID), in which both cellular and
humoral immunity are affected.1 Even though healthy at birth, in-
fants with SCID usually die of severe infections in the first years
of life unless early and effective therapy is provided.1 Usually, the
diagnosis of SCID is hypothesized because of the presence of a
severe infection; at that time, permanent damage can already be
present.1 Therefore an early diagnosis in the preinfection period
is desirable to save affected patients and to afford them good155
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and is already performed in several countries.2 The high mortality
and morbidity rates of the disease, availability of curative thera-
pies, higher effectiveness of those therapies when performed dur-
ing the early presymptomatic phase, and availability of specific
disease markers makes the SCIDs a group of diseases deserving
of newborn screening.3
Purine nucleoside phosphorylase (PNP) deficiency is a rare
form of autosomal recessive combined immunodeficiency (CID),
accounting for approximately 4% of patients with SCID4-6 with a
wide spectrum of immunologic severity up to PNP-SCID. Never-
theless, its true incidence and prevalence remains unknown
because of misdiagnosis and insufficient available laboratory
testing.
PNP is a key enzyme in the purine degradation and salvage
pathway that catalyses phosphorolysis of purine nucleosides and
29-deoxy-nucleosides, such as guanosine, 29-deoxy-guanosine
(dGuo), inosine, and 29-deoxy-inosine (dIno), to their respective
purine bases and pentose-1-phosphates.7 Loss of PNP function
blocks production of xanthine, hypoxanthine, and uric acid and
allows PNP substrates to undergo alternative metabolism to toxic
metabolites. The intracellular accumulation of deoxyguanosine
triphosphate derived from dGuo is thought to be toxic to lymphoid
cells, and this or other effects of PNP deficiency result in various
neurologic abnormalities in up to half of patients with the
condition.6,8
PNP deficiency is both genetically and clinically heteroge-
neous: inheriting alleles with mutations that profoundly decrease
or abolish enzyme activity results in CID, which has a wide
clinical spectrum up to SCID; less detrimental mutations confer
milder phenotypes.8 PNP deficiency should be suspected in a pa-
tient with T lymphopenia, recurrent infections of the upper and
lower respiratory tract caused by common bacterial pathogens
or opportunistic organisms, neurologic abnormalities, autoimmu-
nity, or malignancy.1,4-6,8 Hematopoietic stem cell transplantation
might be curative, at least for the immunologic aspects of the dis-
ease, but its efficacy is higher if performed early to restore
lymphoid cells that express active PNP and provide both immune
function and metabolic detoxification to other organs before irre-
versible damage has occurred.
PNP deficiency is usually diagnosed in already symptomatic
patients by assaying enzyme activity in hemolysates prepared
from fresh or frozen packed erythrocytes, in dried blood spots
(DBSs), or in blood mononuclear cells or fibroblasts. The
diagnosis can also be established or confirmed by means of
analysis of PNP genotype.8 We have recently demonstrated thattandem mass spectrometry (TMS) can easily identify abnormal
metabolites in a similar disorder, SCID, because of inherited defi-
ciency of adenosine deaminase (ADA).9 The specificity and
sensitivity of TMS diagnosis of ADA deficiency is very high
and has a very low cost when used on DBSs during a routine
newborn screening procedure.9,10 Since 2010, a pilot
population-based newborn screening study for SCID has been
started in Tuscany, Italy, using both TMS9,10 and molecular
methods to evaluate T-cell receptor excision circles (TREC)11
and, more recently, kappa-deleting recombination excision cir-
cles (KREC) levels.12 TRECs and KRECs are well-known
markers of primary immunodeficiency disorders used in newborn
screening programs. TREC and KREC levels are evaluated by us-
ing quantitative real-time PCR on DBSs. However, both TREC
and KREC quantitative analysis might fail in identification of
some immunodeficiencies9 and cannot individuate delayed or
late-onset ADA deficiency.
The aim of the present work was to evaluate whether TMS can
identify PNP metabolites in DBSs, with the final goal of finding a
sensitive and reliable tool able to identify patients with PNP-CID
at birth during routine newborn screening.METHODS
Patients
DBS samples from 9 patients with genetically confirmed PNP deficiency
were evaluated. Four of them were from Turkey, 2 were from Germany, 1 was
from Argentina, 1 was from the United Kingdom, and 1 was from Sweden.
DBSs were taken at the time of diagnosis in 7 of these patients (patients 1-7),
although for 2 patients (patients 8 and 9), stored DBSs taken at birth during
routine newborn screening were retrieved and retrospectively tested. The 2
patients (patients 8 and 9) with available DBSs taken at birth came from the
United Kingdom and Sweden.
All patients had severe recurrent infections, neurologic symptoms, or both.
Clinical data are summarized in Table I.Carriers
In addition to samples from affected patients, DBSs from the mother of
patient 1 and both parents from patients 3 and 6 were analyzed. All of them
were single-allele carriers of the mutation and clinically healthy.Guthrie cards from PNP-deficient patients, carriers,
and control subjects
All experiments for the quantitation of PNP substrates were conducted in
compliance with institutional review board guidelines (protocol no. 7949/
2011). Informed consent was obtained from parents or guardians.
As controls, 10,000 DBSs from neonates (9,300 full-term and 700
premature infants weighing <1,800 g) born in the period between January
2012 and May 2013 were analyzed; 240 DBSs from healthy subjects divided
into 4 age groups were also analyzed.
DBSs were obtained from spotted blood on filter paper (903; Whatman
GmbH, Dassel, Germany) immediately after withdrawal of the samples to
prevent further metabolic conversions.Guthrie card collection procedure for newborn
screening
DBS samples are routinely collected from all neonates born in the Tuscany
and Umbria regions of Italy (about 45,000 samples per year). Collection is
recommended at between 48 and 72 hours of life. Blood samples are obtained
by means of heel sticks, spotted on filter paper (903, Whatman GmbH), dried,
and sent daily by courier to the central newborn screening laboratory.
TABLE I. Patients’ clinical data
Age at diagnosis Origin Clinical symptoms Laboratory data
Patient 1 11 mo Turkey Recurrent otitis Lymphopenia, reduced response to mitogens,
low uric acid levels
Patient 2 3 y, 9 mo Turkey Recurrent pneumonia, motor and mental
retardation
Lymphopenia, reduced response to mitogens,
low uric acid levels
Patient 3 1 y, 3 m Turkey Frequent upper airway infections, behavioral
problems
Lymphopenia, reduced response to mitogens,
low uric acid levels
Patient 4 13 y Germany Bronchiectasis, nonprogressive cerebral palsy Lymphopenia, reduced response to mitogens,
low uric acid levels
Patient 5 3 y, 5 mo Germany Recurrent sinusitis, autoimmune
thrombocytopenia, EBV-positive B-cell
lymphoma
Lymphopenia, reduced response to mitogens,
low uric acid levels
Patient 6 3 y, 6 m Argentina Recurrent otitis media and pulmonary
infections, bronchiectasis, spastic lower limb
palsy, autoimmune thrombocytopenia
Lymphopenia, low serum uric acid level
Patient 7 14 mo Turkey Recurrent respiratory tract infections, truncal
hypotonia, failure to thrive
Lymphopenia, reduced response to mitogens,
low uric acid levels
Patient 8 14 y United Kingdom Developmental delay, trunk ataxia, bacterial
pneumonia
Reduced responses to mitogens by lymphocytes
Patient 9 3 y, 6 mo Sweden Veno-occlusive disease; severe pneumonitis;
skin, gut, and renal graft-versus-host disease
after HSCT; nonprogressive global
developmental delay
HSCT, Hematopoietic stem cell transplantation.
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than 40 inborn errors of metabolism of amino acids, organic acids, fatty acids,
and ADA-SCID.9 A pilot study in the Florence area (6000 samples per year) is
also being performed in our laboratory with TREC measurement. All Guthrie
cards are analyzed within 2 days from collection; after use, all cards are stored
and, if not used, discarded after 10 years.
Standards and chemicals
Guanosine, inosine, dGuo, and dIno were purchased from Sigma-Aldrich
(St Louis, Mo); labeled guanosine, inosine, and dGuo to be used as internal
standards (ISs)werepurchased fromCambridge IsotopeLaboratories (Andover,
Mass). Stock solutions of chemical and labeled standards at 100 mmol/L were
prepared in HPLC-grade water and stored at 2208C. Working solutions were
prepared daily from stock solutions. Other reagents, such as HPLC-gradewater,
formic acid, and acetonitrile, were purchased from Panreac (Barcelona, Spain).
TMS and method validation
A Triple-Quad Mass Spectrometer (ABI SCIEX API 4000, Toronto,
Ontario, Canada) equipped with a turbo ion-spray source and coupled to an
analytic HPLC device was used for this study.
The method for individuating PNP metabolites on DBS samples has been
patented (PCTEP2010/070517). Themethod provides quantitative analysis of
different metabolites, among them guanosine, dGuo, inosine, and dIno. The
method has been tested with 10,000 DBSs from healthy newborns. TMS
parameters and method validation details, as well as normal values, are
provided in the Methods section in this article’s Online Repository at www.
jacionline.org. Validation was performed by using calibrators at a known con-
centration of PNP metabolites in terms of linearity, intraday and interday pre-
cision, and accuracy (see Table E1 in this article’s Online Repository at www.
jacionline.org).
Sample preparation for routine screening tests is exactly as reported by la
Marca et al,13 with the exception of the butylation procedure, which is not car-
ried out.
TREC and KREC analysis for patients 8 and 9
Details on TREC and KREC analysis for patients 8 and 9 are provided in
the Methods section in this article’s Online Repository.PNP activity
PNP enzyme activity wasmeasured by using a radiochemical method14 and
adapted for measuring the activity in eluates of DBSs on filter paper.15 For pa-
tient 9, enzyme activity was evaluated on induced pluripotent stem cells.Cost analysis of TMS
Costs for reagents, equipment, and laboratory operators have been
considered to evaluate the total cost of the test per patient. Costs of Guthrie
cards and transport to the newborn screening laboratory were not included
because the test was performed on the same Guthrie card already used for all
other neonatal screening routinely performed in Tuscany.RESULTS
Ten thousand blood spots were tested to establish normal
ranges for PNP metabolites. Moreover, 240 DBSs from healthy
donors were analyzed to establish age-related cutoffs in a
nonneonatal population. We decided to divide the reference
population into 4 age groups.
Furthermore, we investigated whether PNP metabolite accu-
mulation could increase the newborn screening cutoff because of
enzymatic immaturity in preterm neonates. No significant
differences were found by comparing the means and SDs between
the full-term neonate group with those in the premature neonate
group (data not shown). We defined the same reference ranges for
all PNP metabolites in both groups. The reference values for
dGuo, guanosine, inosine, and dIno have been summarized in
Table II. As for control subjects, no false-positive or indetermi-
nate results were found.
All the DBS samples obtained from the 9 patients with
confirmed PNP-CID demonstrated high levels of inosine, dIno,
guanosine, and dGuo compared with those in control subjects. In
patients 1 to 7, for whom neonatal DBSs were not available, the
metabolite measurement was performed on DBS samples pre-
pared at the timewhen PNP deficiency was diagnosed (11 months
TABLE II. Reference values for dGuo, guanosine, inosine, and
dIno
dGuo
(mmol/L)
Guanosine
(mmol/L)
Inosine
(mmol/L)
dIno
(mmol/L)
Newborns 0.09 1.50 20.70 0.28
1-6 mo 0.01 0.29 41.86 0.68
6 mo-5 y 0.01 0.29 21.74 0.33
5-15 y 0.01 0.22 17.92 0.41
>15 y 0.01 0.18 13.85 0.43
Values are calculated as medians 1 2 SDs.
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analysis performed on neonatal DBSs taken and stored in their
country of origin (Table I).
In the 5 adult carriers concentrations of all metabolites within
normal ranges were found.
Fig E1 in this article’s Online Repository at www.jacionline.
org shows levels of the 4metabolites in 2 patients (1 tested at birth
and the other tested at the age of diagnosis), 1 representative con-
trol subject, and a carrier.
TREC and KREC assays were performed only for patients 8
and 9, for whom neonatal DBSs were available. Levels are shown
in Table III.16-19
The activities of PNP in cells from patients 1 to 8 and in
induced pluripotent stem cells from patient 9 and the results from
sequence analysis of the PNP gene are presented in Table III.
Enzyme activity was defective in all patients, with the exception
of patient 5, who had borderline values.
As previously described for ADA screening using TMS,9 no
extra instruments and no extra operator timewere necessary other
than the time required for routine neonatal screening. Therefore
the cost is calculated for reagents only and is approximately
V0.01 ($0.013) per DBS tested.
DISCUSSION
The results of the present study demonstrate that TMS can
quantify purine metabolites on DBSs to identify patients with
PNP deficiency. The method can identify PNP-deficient patients
at birth on DBSs taken during the newborn screening procedure,
thereby allowing early diagnosis and the most effective thera-
peutic intervention.
The sensitivity and specificity of the described method were
tested by using retrospective analysis of DBSs from 9 patients
with a genetically confirmed diagnosis of PNP deficiency and on a
group of 10,240 DBSs from healthy control subjects. All patients
with PNP-CIDwere identified based on PNPmetabolite levels out
of the normal range, even those neonatal DBSs (patients 8 and 9)
in which TREC or KREC analysis results were not out of normal
ranges and in 1 unique case in which a deficiency of PNP
enzymatic activity in the DBS sample was not diagnostic.
Actually, because there is no overlapping between metabolite
levels of PNP-deficient patients and control subjects, the risk of
false-positive and false-negative results is extremely low. Exper-
imental data showed some differences in median values of age-
related metabolite concentrations (Table II). These results could
be due to different enzymatic metabolism related to dietary
intake, cellular turnover, or growth curve in newborns compared
with older subjects.
In addition, the method is applicable to premature infants,
whose mean PNP metabolite levels do not differ from thosefound in full-term babies. Levels of all PNP metabolites in the 5
carrier subjects were comparable with those seen in healthy
control subjects. These data were not unexpected because
similar results had been obtained with TMS analysis of carriers
of ADA deficiency.9 Enzymatic activity had been previously
tested in parents of PNP-deficient patients (Hershfield M, per-
sonal communication); it was approximately 50% of normal ac-
tivity, and therefore it is not surprising that PNP metabolite
levels are not increased in carriers. We could not test patients
at different times of life, and therefore we cannot demonstrate
in this study whether metabolite levels remain at the same level
during the lifespan. Studies are now going on in our laboratories
to answer this question. However, data obtained in patients with
ADA deficiency, which has a similar pathogenesis, suggest that
metabolite levels strongly correlate with both genetic variant
and enzymatic activity and therefore tend to remain stable
throughout life.10
TMS could be a useful tool for this follow-up study because it is
very easy to perform and inexpensive. No extra operator time is
necessary for sample preparation or analysis other than the time
required for routine neonatal screening. Similarly, no extra
equipment is necessary, and instruments are not used for longer
times. Therefore the cost is calculated for reagents only; including
unavoidable reagent waste, the cost is V0.01 ($0.013) per test.
Moreover, TMS could be applied in the follow-up period to
evaluate how PNP metabolites are affected by a treatment like
hematopoietic stem cell transplantation.
It is well known that the immune defect observed in
PNP-deficient patients can be heterogeneous, with predominance
of either T- or B-cell defects in different patients. This aspect
might reflect what we found in TREC and KREC analysis on
DBSs obtained at birth. Actually, in the 2 patients whose neonatal
DBSs were available, TREC and KREC levels were not
concordant. Both TREC and KREC levels tended to be low in
both patients, but although in patient 8 TREC levels were
borderline and not reported as pathologic in the presence of
absolutely abnormal KREC levels, in patient 9 TRECs were
undetectable, whereas KREC levels were reported as normal. Our
data suggest that, as previously demonstrated for ADA deficiency,
TREC10,20 or KREC measurement, when used alone (data not
shown), can fail to identify an affected patient, whereas TMS
has a higher sensitivity. However, our data on TREC and KREC
efficiency in PNP diagnosis at birth should be completed in larger
studies because no definitive conclusion can be drawn from the
limited number of neonatal DBSs studied.
The data also suggest that the 2 tests (TREC and KREC
measurement) should be used together to catch the highest
number of patients with SCID.12 The combination of the TREC
plus KREC assay can maximize the effect of identifying various
types of patients with SCID.
The finding that dIno and dGuo levels in DBSs taken at birth
range between similar values to those found in samples taken at
the time of diagnosis suggests that metabolites do not progres-
sively accumulate during life, but as similar for ADA deficiency,
toxic levels of metabolites might already be present at birth. The
use of TMS for PNP measurement, together with established
routine newborn screening programs, would raise suspicion of
PNP deficiency at an extremely early age, thereby giving the
clinician the opportunity to confirm the diagnosis (by using an
enzyme assay and genotyping) and to initiate the appropriate
therapy in time.
TABLE III. Purine levels, genetic analysis, and enzymatic activity in 9 patients with PNP-CID
Patient
no.*
Age at DBS
collection
Guanosine
(mmol/L)
dGuo
(mmol/L)
Inosine
(mmol/L)
dIno
(mmol/L)
PNP activity
(nmol/h/mg
[normal value,
1684 6 561])
PNP
genotype
allele 1
PNP
genotype
allele 2
TREC
copies/mL
(normal
value, >10)
KREC
copies/mL
(normal
value, >8) Reference
1 11 mo 6.8 4.3 74.8 2.1 0.0 c.287delT; V96fs c.548delA; E183fs Hershfield (personal data)
2 3 y, 9 mo 6.0 4.3 50.9 0.9 2.5 IVS3-18 G>A IVS3-18 G>A Markert et al16
3 1 y, 3 mo 5.5 6.3 454.6 2.2 12.1 P198L P198L Hershfield (personal data)
4 13 y 2.9 2.8 34.3 1.3 18.4 A117T A117T Grunebaum et al17
5 3 y, 5 mo 1.7 0.2 27.1 2.3 683.0 c.387_389 delCAT c.387_389 delCAT Markert et al16
6 3 y, 6 mo 2.9 3.2 31.5 1.7 24.5 R58X E89X Dalal et al18
7 14 mo 2.6 0.2 283.3 5.5 0.0 R58X R58X
8 At birth 3.7 7.4 192.6 17.3 16.0 N243K Y249S 13.5 4.2 Our data
9 At birth 7.1 3.4 50.2 1.3 0.0 D128G D128G 0 30 Aust et al19
*Per age reference values (Table II).
Novel mutations.
Enzyme activity measured in induced pluripotent stem cell lines (normal value, 288-4018).
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newborn screening by using TMS. Detection of PNP metabolites
by using TMS could be performed on the same DBSs collected at
birth for routine screening tests and the method could be easily
included in a population-based screening program because of its
low cost and because it does not require extra equipment or extra
time for operators already working in TMS screening programs.
The absence of follow-up visits or blood examinations caused in
screening based on other methods by the presence of false-
positive results would further increase the cost-effectiveness of
this method. The inclusion of a disease into newborn screening
panels depends on disease frequency and other factors and,
among them, the sensitivity/specificity of the available screen
tests, as well as their cost.
Even though PNP-deficient patients with early and delayed
onset could be identified by using combined TREC and KREC
screening programs, abnormal TREC levels, KREC levels, or
both would require further functional analysis, whereas the TMS
method would readily identify the enzymatic defect in both a
specific and direct way.
Therefore, given the very low cost of the TMS tests, we suggest
that PNP be included in the newborn screening panel in all
newborn screening laboratories using TMS.
Clinical implications: TMS can measure PNP metabolite levels
on newbornDBSs. It is a sensitive, specific, and inexpensive tool.
PNP deficiency can be included in the TMS newborn screening
panel.
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TMS
ATriple-Quad Mass Spectrometer (ABI SCIEX API 4000) equipped with
the turbo ion-spray source and coupled to an analytic HPLC device was used
for this study. The turbo ion-spray source operated under positive ionmode at a
voltage of 5500 V and under a ‘‘turbo’’ gas flow of 10 L/min of air heated to
5008C (nominal heating gun temperature).
Declustering potential, collision exit potential, and collision energy were
automatically optimized for guanosine, inosine, dGuo, dIno, 15N5-Guo,
15N4-Ino, and
2H2-dGuo by using the quantitation optimization option. The
resulting declustering potential was 30 V for all of them. Optimal collision
exit potential was 10 V for all metabolites, and labeled ISs and collision en-
ergies were found at 16 V for guanosine and 15N4-Guo; 14 V for inosine,
dGuo, 15N4-Ino, and
2H2-dGuo; and 13 V for dIno.
Mass spectrometric and TMS spectra were collected in continuous-flow
mode by connecting the infusion pump directly to the turbo ion-spray source.
Standard solutions of 1 ng/mL for guanosine, inosine, dGuo, dIno, 15N5-Guo,
15N4-Ino, and
2H2-dGuo in an aqueous solution of 50% methanol containing
0.1% formic acid were infused at 7 mL/min. From these experiments, the re-
sulting ion-pair transitions for the quantitative experiment are as follows:
284.2 > 152.1 and 289.2 > 157.1 for guanosine and 15N5-Guo, respectively;
269.2 > 137.1 and 273.2 > 141.1 for inosine and 15N4-Ino, respectively;
268.2 > 152.1 and 270.2 > 152.2 for dGuo and 2H2-dGuo, respectively; and
253.2 > 137.1 for dIno. The extracted samplewas injected into an electrospray
triple-quadrupole tandem mass spectrometer with the aid of an automated
liquid-handling device. Mass spectral data for the amino acids were acquired
through a neutral loss scan of 46 Da; mass spectral data for the acylcarnitines
were acquired through a precursor ion scan of 85 Th. Mass spectral data for
purines, including adenosine and deoxyadenosine, and succinylacetone were
acquired through multiple-reaction monitoring. The percentage of each ana-
lyte recovered was determined through comparison with an IS for each
analyte.
Method validation
The method for individuating PNP metabolites on DBS samples has been
patented (PCTEP2010/070517). Themethod provides quantitative analysis of
different metabolites, among them guanosine, dGuo, inosine, and dIno. The
method was validated by the use of calibrators at known concentration of PNP
metabolites in terms of linearity, intraday and interday precision, and accuracy
(Table E1). Calibrators containing ISs at 10 mmol/L were at concentrations of
0, 1, 10, 50, and 100 mmol/L for guanosine, dGuo, inosine, and dIno,
respectively.
Reference standard blood spot calibrators were prepared at known
concentrations of guanosine, dGuo, inosine, and dIno by using a pooled
whole-blood sample from 3 healthy adult donors. A 20-mL volume of spiked
blood was dispensed onto filter paper cards and dried for at least 3 hours at
room temperature.
A small disk (3.2 mm) of a DBS was punched and deposited in a well of a
microwell plate. The sample was extracted by dispensing 300 mL of an
extraction solution consisting of a mixture of methanol and aqueous solution
of 3 mmol/L hydrate hydrazine at an approximate relative volume/volumeratio of 66.6% and 33.3%, respectively. ISs for amino acids, acylcarnitines,
succinylacetone, and purines (adenosine, deoxyadenosine, guanosine, dGuo,
and inosine) were also present in the extract solution. The extracted sample
was injected into an electrospray triple-quadrupole tandemmass spectrometer
with the aid of an automated liquid-handling device. The percentage of each
analyte recovered was determined through comparison with an IS for each
analyte. Considering the unavailability of a commercially labeled IS of dIno,
the quantitation of this metabolite was performed by means of external
calibration with 15N4-Ino as the IS. The imprecision of the assay was deter-
mined by analyzing the samples described in Table E1. Each sample run con-
sisted of 10 punches of each sample, which were processed and measured as
previously described. The study included 10 such runs a day for a total of 10
days. With this information, the within-run, between-run/within-day, and
between-day imprecision components were determined, from which the total
imprecision was determined. The results of the imprecision analysis of guano-
sine, dGuo, inosine, and dIno are shown in Table E1.
TREC and KREC analysis for patients 8 and 9
DNAwas eluted from a single 3.2-mmpunch of the original Guthrie card of
patient 8, as described previously,E1-E3 and DNAwas extracted according to a
previously described homemade procedure.E3 Quantitative triplex real-time
quantitative PCR for TRECs, KRECs, and b-actin (ACTB) was performed
on a ViiA7 real-time PCR system (Applied Biosystems, Foster City, Calif),
as previously described,E3 for patient 7. The quantitative PCR procedure
was optimized based on custom reagents provided byAffymetrix (Santa Clara,
Calif). TREC and KREC levels were normalized per microliter of blood,
assuming that a single 3.2-mm punch contains approximately 3 mL of whole
blood. Abnormal TREC/KREC screening results were defined as less than 8
TRECs/mL and less than 6 KRECs/mL of dried blood based on cutoff values
according to current prospective trials in Germany and Sweden.
As for patient 9, 3 punches from the regular screening card were obtained,
and DNA was extracted according to the manufacturer’s instructions for the
QIAamp DNA Mini kit (Qiagen, Hilden, Germany). Two duplex real-time
quantitative PCRs (TREC1ACTB and KREC1ACTB) were performed on
DBSs from patient 9, as previously described.E1 The previously described
method was usedE1 for both TREC and KRECmeasurements, with diagnostic
cutoff scores at 10 TRECs/mL and 8 KRECs/mL. TREC and KREC analysis
was always performed on the same samples used for TMS test.
Amplification of ACTB was used to assess the success of DNA extraction
from the Guthrie cards.
FIG E1. PNP marker profile in DBSs determined by using TMS analysis. A, Healthy control subject. B, PNP
carrier. C, Patient 2 at the age of diagnosis. D, Retrospective analysis on neonatal card of patient 8. Guo,
Guanosine; Ino, inosine.
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TABLE E1. Intra- and interday imprecision and accuracy for
PNP metabolites evaluated for method validation
Investigated
metabolite
Spiking
(mmol/L)
Intraday
imprecision
(%), n 5 10
Interday
imprecision
(%), n 5 10
Average
readings
(mmol/L)
Accuracy
(%)
Guanosine 1 4.1 1.9 0.8 82
10 13.7 9.3 12.3 123
50 11.5 6.4 57.5 115
100 5.8 8.7 97.4 97
dGuo 1 6.3 4.8 1.3 125
10 2.0 9.2 12.0 120
50 2.7 15.2 49.4 99
100 2.5 5.2 93.1 93
Inosine 1 3.2 4.7 1.0 99
10 3.4 14.6 10.5 105
50 2.2 9.5 49.5 99
100 1.9 13.5 96.3 96
dIno 1 19.5 19.8 1.2 116
10 5.0 7.3 11.4 114
50 3.0 9.5 50.0 100
100 1.9 8.0 101.0 101
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